Prognostic Value of CRP–Albumin–Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Breast Cancer
Jiaru Zhuang,Shan Wang,Yuan Wang,Yibo Wu,Renjing Hu
DOI: https://doi.org/10.2147/ijgm.s447201
IF: 2.145
2024-03-16
International Journal of General Medicine
Abstract:Jiaru Zhuang, 1, &ast Shan Wang, 2, &ast Yuan Wang, 2 Yibo Wu, 2 Renjing Hu 1 1 Department of Laboratory Medicine, Jiangnan University Medical Center, Wuxi, People's Republic of China; 2 Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Renjing Hu, Department of Laboratory Medicine, Jiangnan University Medical Center, 68 Zhongshan Road, Wuxi, Jiangsu, 214000, People's Republic of China, Email Yibo Wu, Human Reproductive and Genetic Center, Affiliated Hospital of Jiangnan University, 1000 Hefeng Road, Wuxi, Jiangsu, 214000, People's Republic of China, Email Purpose: According to the 2023 global cancer data, breast cancer is the most common malignant tumor among women in the world. Its occurrence and development is influenced by inflammation, nutrition, and immune status. Therefore, this study combines C-reactive protein (CRP), albumin, and lymphocyte, which can reflect the above states, to form the CRP-albumin-lymphocyte (CALLY) index, an indicator to evaluate its relationship with overall survival (OS) and disease-free survival (DFS) in breast cancer patients. Patients and Methods: We retrospectively analyzed the clinical and follow-up data of 174 patients with breast cancer. The optimal cutoff for the preoperative CALLY index was identified by considering the area under the receiver operating characteristic curve; subsequently, the discriminatory ability of the cutoff was determined. The effect of the CALLY index on overall survival (OS) and disease-free survival (DFS) was analyzed using the Kaplan–Meier method and the Cox proportional hazards model. The CALLY index was calculated as: (Albumin × Lymphocyte)/(CRP × 10 4 ). Results: The cut-off value of the CALLY index was determined at 2.285. With a cut-off value of 2.285, patients were divided into two groups: those with CALLY < 2.285 and those with CALLY ≥ 2.285. CALLY Index ≥ 2.285 was associated with better survival outcomes. Multivariate Cox analysis showed that TNM stage and CALLY index were prognostic factors that affected OS and DFS. Conclusion: The CALLY index is a new prognostic biomarker for breast cancer patients after surgery. This new CALLY index allows for suitable patients with a poor prognosis to receive postoperative adjuvant therapy. Keywords: breast cancer, prognosis, CALLY index, survival Breast cancer (BC) is one of the most common cancers among women. This malignant tumor has a harmful impact on patients quality of life and is a significant public health issue. 1 Recent data from China shows that the incidence of breast cancer is significantly increasing, especially in developed coastal cities. 2 Experts predict that in the future, the incidence rate of breast cancer in China will reach a staggering 100 cases per 100,000 postmenopausal women. 3 Although the current treatment methods for breast cancer include surgery, adjuvant chemotherapy, radiation therapy, targeted therapy, immunotherapy, and traditional Chinese medicine, the outcomes for patients are still unsatisfactory. 4 Therefore, there is an urgent need for effective and accessible methods for BC patients to optimize risk stratification and predict postoperative survival outcomes. The development of breast cancer is influenced by many factors, including inflammation levels, nutritional status, and immune function. 5 Cancer-related systemic inflammatory response is a key indicator of tumor progression, and patients with breast cancer and higher levels of inflammation have a higher risk of death than those with lower levels of inflammation. 6,7 Nutritional status also plays an important role in the prognosis of breast cancer patients, and research has shown that malnutrition is associated with poorer overall survival (OS) in breast cancer patients. 8 In addition, good immune function is the main defense against the progression of breast cancer. It has been reported that the prognosis of breast cancer patients with poor immune function is much worse than that of patients with good immune function. 9 Based on the above theories and research, we believe that indicators that comprehensively reflect inflammation levels, nutritional status, and immune function can better predict the prognosis of breast cancer patients. In previous studies, hematological indicators have commonly been used to reflect inflammation levels, nutritional status, and prognosis. 10 Firstly, C-reactive protein (CRP) is a common clinical indicator that can reflect the level of inflamma -Abstract Truncated-
medicine, general & internal